Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGX-6150 in chronic hepatitis C
NCT02027116Phase 1Completed
- Sponsor
- GeneOne Life Science, Inc.
- Start
- Jan 2014
- Primary completion
- Jul 2015
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of INO-8000 in hepatitis C (HCV) (3 arms), sponsored by GeneOne Life Science, Inc. Primary endpoint: Safety and Tolerability at Week 36. Started Jan 2014; status: completed.
02
Drugs
INO-8000
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02027116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02027116.